Latest Biotech News

OpenAI announced ChatGPT for Healthcare, a product intended to integrate the company’s large language models with hospital systems, followed by the consumer‑facing ChatGPT Health feature that...

GSK and Ionis reported that bepirovirsen, an antisense oligonucleotide, met primary endpoints in two pivotal Phase 3 trials and achieved functional cure rates in chronic hepatitis B patients. The...

Alveus Therapeutics emerged with about $160 million in Series A capital to advance a Phase‑2‑ready obesity candidate that targets the same dual pathways as Amgen’s MariTide, plus an...

Storm Therapeutics announced a collaboration with Alida Biosciences to apply AlidaBio’s EpiPlex/EpiScout epitranscriptome platforms to clinical samples from patients treated with Storm’s METTL3...

Aktis Oncology completed a $318 million initial public offering and will trade on Nasdaq under ticker AKTS. The Boston-based radiopharmaceutical developer priced 17.65 million shares at $18 each...

Eli Lilly agreed to acquire San Diego–based Ventyx Biosciences for about $1.2 billion in an all‑cash deal at $14 per share, a roughly 62% premium to the recent trading average. Ventyx’s lead...

Parabilis Medicines closed a $305 million Series F round led by RA Capital, Fidelity and Janus Henderson to advance its Helicon peptide platform and lead candidate zolucatetide toward later‑stage...

Immuneering released updated Phase IIa data for atebimetinib combined with modified gemcitabine/nab‑paclitaxel in first‑line pancreatic cancer, reporting a 64% overall survival rate at 12 months...

GSK and Ionis reported that their antisense therapy bepirovirsen met primary endpoints across two pivotal Phase III studies, achieving statistically meaningful functional cure rates in chronic...

Storm Therapeutics entered a strategic collaboration with Alida Biosciences to quantify transcript‑specific N6‑methyladenosine (m6A) RNA modifications in clinical samples from patients treated...

EpiBiologics closed a $107 million Series B, backed by investors including GV and Johnson & Johnson’s venture arm, to advance its surface‑targeted protein degradation platform (EpiTACs) and lead...

OpenAI announced ChatGPT for Healthcare, a tailored offering that brings the ChatGPT conversational AI into hospital and health‑system workflows. The launch follows consumer health features and is...

Illumina appointed Eric Green, former director of the National Human Genome Research Institute, as its chief medical officer effective Feb. 2. Green succeeds a vacancy in Illumina’s medical...

Alveus Therapeutics emerged with a $159.8–$160 million Series A to advance a Phase‑2 ready obesity candidate that targets the same two pathways as Amgen’s MariTide, with claims of potential dosing...

Eli Lilly agreed to acquire San Diego-based Ventyx Biosciences in a roughly $1.2 billion all-cash deal to gain control of clinical-stage NLRP3 inhibitors. Lilly priced the transaction at $14 per...

Aktis Oncology completed a $318 million Nasdaq initial public offering, marking biotech’s first IPO of 2026. The Boston-based radiopharmaceutical developer priced 17.65 million shares at $18...

Parabilis Medicines raised $305 million in a Series F financing to push its Helicon platform and lead candidate, zolucatetide, toward later-stage testing. The round, led by RA Capital, Fidelity...

EpiBiologics closed a $107 million Series B to advance its EpiTAC platform and first-in-human candidate EPI-326, a bispecific antibody designed to degrade tumor-surface proteins such as mutant...

GSK and Ionis announced positive topline results from two pivotal Phase 3 studies (B‑Well 1 and B‑Well 2) testing bepirovirsen, an antisense oligonucleotide for chronic hepatitis B. The programs...

Immuneering updated Phase IIa data showing its oral MEK inhibitor atebimetinib, given with modified gemcitabine/nab‑paclitaxel chemotherapy, was associated with a 64% overall survival rate at 12...